The MBC at the Royal Melbourne Hospital has expanded its program of internationally competitive neuroscience research, with a mission to deliver lasting translational impact and improve the lives of patients with common brain diseases.
Research at the MBC is focused on translating clinical neuroscience research into improved clinical practice, policy and patient outcomes.
Generate new knowledge related to common brain diseases to improve outcomes for sufferers of brain disease
Translate research findings into new guidelines
for clinical practice
Train the next generation of international leaders in
Build strong collaborative relationships with other neuroscience institutes both nationally and internationally.
Engage with the community and industry to improve
support for neuroscience research
A centre for patient-driven neuroscience and novel technologies
The 500 metres squared MBC is embedded in the RMH clinical neurology environment and includes dedicated clinical trial space, and labs for neuroimaging and data analysis. The hub facilitates collaborations between the different clinical neuroscience groups at Melbourne Health and the University of Melbourne encompassing a diverse community of researchers in disciplines such as allied health, nursing, neural engineering, medical imaging, epidemiology, health economics, and health informatics.
The MBC has continued the formative tradition of research in partnership, working closely with The Royal Melbourne Hospital, The Florey Institute of Neuroscience and Mental Health, The University of Melbourne and the Victorian government.
The MBC and its partners have continued to make strides in the translation of neuroscience research into improved patient outcomes.
The past two years have been a period of tremendous growth at the MBC-RMH. We have farewelled Professor Helmut Butzkueven and Professor Terry O’Brien, who have passed the reins to new leaders in Multiple Sclerosis and Epilepsy research. Importantly, we have warmly welcomed internationally renowned stroke neurologist and trialist, Professor Mark Parsons, who has taken on the role of Director of Neurology at RMH.
We also welcomed our new Dementia Research team, led by Associate Professor Amy Brodtmann. Neuroimaging expert Dr Andrew Bivard will oversee our pivotal new study of post-stroke fatigue, further concentrating internationally leading expertise in our hub of translational neuroscience. We are excited to announce the creation of the Clinical Outcomes Research (CORe) Unit led by Associate Professor Tomas Kalincik, who will also take over as Co-Head of MS. We have achieved enormous success in the past 8 years. Our capacity has expanded, our research programs have delivered major clinical impacts internationally and innovative new collaborations are on the horizon.
The mobile stroke unit in particular has been a key focus and high-profile achievement for the centre’s stroke research team and our major partners. Our symposia continues to bring together our diverse network, including researchers, clinicians, research nurses, students, and also consumer representatives, all of whom engage in developing new strategies and research foci.
I am grateful to all our team and particularly want to thank the MBC executive team for their leadership and support during two years of extensive centre-wide growth and transformation, and the launch of major new clinical trials. I look forward to more exciting developments as the MBC RMH movies into its next phase of world-leading innovation in clinical neuroscience.
Professor Stephen Davis
“The Melbourne Brain Centre at Royal Melbourne Hospital has achieved enormous success in the last 8 years. Our capacity has expanded, our research programs have delivered major international impacts and innovative new collaborations are on the horizon.”